## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%); PEG 1.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($69.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Burgundy Asset Management Ltd. Sells 27,936 Shares of Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251207T110756 | Somewhat-Bullish | Relevance: 99%
-  Burgundy Asset Management Ltd. reduced its stake in Henry Schein, Inc. by selling 27,936 shares, leaving it with 2,207,493 shares, which constitutes about 1.82% of the company. Despite the sale, Henry Schein reported strong Q2 results, exceeding EPS and revenue expectations, and issued positive FY2025 guidance. Several analysts have raised their price targets for HSIC, though the consensus remains a "Hold" with a target price of $76.17.

**2. Henry Schein to renominate KKR designees to board for 2026 term By Investing.com**
- Source: Investing.com South Africa | 20251209T130809 | Bullish | Relevance: 99%
- Henry Schein Inc. announced it will renominate Max Lin and William K. Daniel, KKR designees, for election to its board of directors at the company's 2026 annual meeting, with their term expiring at the 2027 meeting. This decision follows an extension exercised by KKR Hawaii Aggregator L.P. under a Strategic Partnership Agreement. The company also recently reported strong Q3 2025 earnings and expanded its distribution agreement with vVARDIS.

**3. 409,100 Shares in Henry Schein, Inc. $HSIC Acquired by Oribel Capital Management LP**
- Source: MarketBeat | 20251207T120903 | Somewhat-Bullish | Relevance: 98%
-  Oribel Capital Management LP has acquired a new stake of 409,100 shares in Henry Schein, Inc. (NASDAQ:HSIC) valued at approximately $29.885 million, making it their 25th largest holding. Other institutional investors also adjusted their positions in the company. Henry Schein's stock opened at $73.62, showing a 0.4% increase, with a market capitalization of $8.67 billion.

**4. Henry Schein to renominate KKR designees to board for 2026 term**
- Source: Investing.com | 20251209T132633 | Bullish | Relevance: 98%
-  Henry Schein, Inc. announced its decision to renominate Max Lin and William K. Daniel, both KKR designees, to its board of directors for election at the company's 2026 annual meeting. This move follows KKR Hawaii Aggregator L.P.'s exercise of an extension election under a Strategic Partnership Agreement. The company also reported strong Q3 2025 earnings and an expanded distribution agreement with vVARDIS for Curodont Repair Fluoride Plus.

**5. Revenue per share of Henry Schein, Inc. â€“ SWB:HS2**
- Source: TradingView | 20251207T031435 | Neutral | Relevance: 98%
-  This article provides a financial snapshot of Henry Schein, Inc. (SWB:HS2), specifically focusing on its revenue per share. It presents a table showing period values and percentage changes for this metric, indicating the company's financial performance.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.8B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 7.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 13.8 |
| Current P/E | 14.9 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.3% to -2.1% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.12% (CS: 33) | Weak |
| RSI_14 | 55.7 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $72.86
- **Stop Loss:** $69.66 (4.4% risk)
- **Target:** $76.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 156
- **Position Value:** $11,366.16
- **Portfolio %:** 11.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-24 (Est: $1.29)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*